DAWN - Day One Biopharmaceuticals, Inc.

QQQ $ 445.88 $ 1.10 (0.25 %)

DIA $ 395.58 $ 1.12 (0.28 %)

SPY $ 523.16 $ 2.25 (0.43 %)

TLT $ 90.86 $ 0.51 (0.56 %)

GLD $ 218.12 $ 1.87 (0.86 %)

Previous Close

$ 16.62

Open

$ 16.36

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 16.14 - $ 16.62

52 Week Range

$ 9.67 - $ 18.07

Volume

467,496

Average Volume

Market Cap

1.39B

Beta (5Y Monthly)

$ -0.24

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-06-2024	03-31-2024	10-Q
2	02-26-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-01-2023	03-31-2023	10-Q
6	03-06-2023	12-31-2022	10-K
7	11-07-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-07-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-10-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Maintains Buy on Day O...
05/07/2024 10:53:34

HC Wainwright & Co. analyst Andres Maldonado maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the...

Needham Reiterates Buy on Day One Biopharm...
05/07/2024 09:56:59

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.

Day One Biopharmaceutical Q1 2024 GAAP EPS...
05/06/2024 20:33:28

Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.72) per share which missed the analyst consensus estim...

Needham Reiterates Buy on Day One Biopharm...
04/25/2024 09:29:48

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.

HC Wainwright & Co. Reiterates Buy on Day ...
04/24/2024 10:09:58

HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains...

Needham Maintains Buy on Day One Biopharma...
04/24/2024 09:28:52

Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and raises the price target from $30 ...

$day-ones-ojemda-receives-us-fda-accelerated-approval-for-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma$

Day One's OJEMDA Receives U.S. FDA Acceler...
04/23/2024 19:58:58

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rear...

JP Morgan Maintains Overweight on Day One ...
04/22/2024 14:30:08

JP Morgan analyst Anupam Rama maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price targe...

Piper Sandler Maintains Overweight on Day ...
03/26/2024 11:59:47

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and maintains $40...

Piper Sandler Maintains Overweight on Day ...
02/28/2024 15:45:40

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and lowers the pr...

Goldman Sachs Maintains Buy on Day One Bio...
02/27/2024 16:16:22

Goldman Sachs analyst Andrea Tan maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target fr...

Oppenheimer Reiterates Perform on Day One ...
02/27/2024 12:36:02

Oppenheimer analyst Matthew Biegler reiterates Day One Biopharmaceutical (NASDAQ:DAWN) from Perform to Perform.

Day One Cash, Cash Equivalents And Short-T...
02/26/2024 21:42:31

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 t...

Day One Biopharmaceuticals Reveals Tovoraf...
11/17/2023 12:05:55

Analyst Ratings for Day One Biopharmaceutical
11/07/2023 19:00:11

Wedbush Maintains Outperform on Day One Bi...
11/07/2023 15:55:09

Wedbush analyst Robert Driscoll maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Outperform and lowers the price tar...

Needham Reiterates Buy on Day One Biopharm...
11/07/2023 11:55:49

Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $34 price target.

Day One Biopharmaceutical Q3 EPS $(0.54) D...
11/06/2023 22:34:00

Day One Biopharmaceutical (NASDAQ:DAWN) reported quarterly losses of $(0.54) per share. This is a 1.89 percent decrease over lo...

Western Digital, JinkoSolar, Lumentum Hold...
10/30/2023 14:19:29

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording...

Market-Moving News for October 30th
10/30/2023 12:50:10

DCPH: 38% | Deciphera Pharma shares are trading higher after the company announced its study of patients with TGCT met its prim...